Deep Track Capital is an investment firm exclusively focused on the life sciences industry, particularly biotechnology and healthcare. The firm's strategy involves forming long-term partnerships with public and pre-IPO companies, providing capital, strategic guidance, and leveraging their network through a fundamentally driven, research-intensive approach.
100% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 8 prior). Their most common stage is series-b (40% of deals). Average disclosed round size is $155.3M (across 20 rounds with reported amounts).
Portfolio
20
Fund Size
$5.1B
Top Stage
Series B
Last 12 Mo
4
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
20 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ambrosia Biosciences Inc. | Series B | $100M | Mar 2026 |
 Tubulis | Series C | $308M | Oct 2025 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Attovia Therapeutics | Series C | $90M | Apr 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
 Arbor Biotechnologies Inc | Series C | $73.9M | Mar 2025 |
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
| RRAPT Therapeutics, Inc. | Series D | $150M | Dec 2024 |
 35Pharma Inc. | Series C | $53M | Nov 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
| IInventiva | Unknown | $410M | Oct 2024 |
 Triveni Bio Inc. | Series B | $115M | Oct 2024 |
 Carmot Therapeutics | Series E | $150M | May 2023 |
 Hemab Therapeutics | Series B | $135M | Feb 2023 |
 Apogee Therapeutics | Series B | $149M | Dec 2022 |
| Arbor Biotechnologies Inc | Series B | $215M | Nov 2021 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 Artios Pharma Limited | Series C | $153M | Jul 2021 |
 Jade Biosciences | Unknown | $95M | — |
| OOruka Therapeutics | Growth | $275M | — |
Top Co-Investors
RA Capital Management6 shared
Frazier Life Sciences5 shared
RTW Investments5 shared
Janus Henderson Investors5 shared
Logos Capital5 shared
BVF Partners LP5 shared
Invus4 shared
Braidwell LP4 shared
Surveyor Capital4 shared
Samsara BioCapital4 shared
Perceptive Advisors4 shared
Cormorant Asset Management3 shared
OrbiMed3 shared
Access Biotechnology3 shared
Soleus Capital3 shared
Redmile Group3 shared
Marshall Wace3 shared
Fairmount3 shared
Last updated: 12 April 2026